Heron Therapeutics, Inc.
HRTX
Rank in Stocks
#21279
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating... Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Share Price
$0.3706
Last synced: 2026-11-09
Market Cap
$70.36M
Change (1 day)
26.48%
Change (1 year)
-68.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Heron Therapeutics, Inc. (HRTX)
Category
Healthcare
EPS for Heron Therapeutics, Inc. (HRTX)
EPS as of June 2026 TTM: $-0.19
According to Heron Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.19. At the end of 2025 the company had an EPS of $-0.12, a decrease compared to its 2024 EPS of $-0.09.
EPS history for Heron Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.19 | 58.33% |
| 2025 | $-0.12 | 34.68% |
| 2024 | $-0.09 | -88.86% |
| 2023 | $-0.80 | -52.10% |
| 2022 | $-1.67 | -25.45% |
| 2021 | $-2.24 | -10.40% |
| 2020 | $-2.50 | 0.00% |
| 2019 | $-2.50 | 2.46% |
| 2018 | $-2.44 | -33.15% |
| 2017 | $-3.65 | -20.13% |
| 2016 | $-4.57 | 54.92% |
| 2015 | $-2.95 | 2.79% |
| 2014 | $-2.87 | -16.08% |
| 2013 | $-3.42 | 79.06% |
| 2012 | $-1.91 | 61.86% |
| 2011 | $-1.18 | -68.11% |
| 2010 | $-3.70 | -39.84% |
| 2009 | $-6.15 | -59.03% |
| 2008 | $-15.01 | -27.94% |
| 2007 | $-20.83 | -131.23% |
| 2006 | $66.70 | -355.07% |
| 2005 | $-26.15 | -18.79% |
| 2004 | $-32.20 | 89.63% |
| 2003 | $-16.98 | 14.65% |
| 2002 | $-14.81 | 49.29% |
| 2001 | $-9.92 | -129.52% |
| 2000 | $33.60 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -8,342.11% |
US
|
|
| $-7.07 | 3,621.05% |
US
|
|
| $-5.29 | 2,684.21% |
AU
|
|
| $12.88 | -6,879.00% |
BE
|
|
| $21.56 | -11,447.37% |
NL
|
Questions about Heron Therapeutics, Inc.'s earnings per share (EPS)
What is Heron Therapeutics, Inc.'s earnings per share (EPS)?
Heron Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.19, as of Jun 2026.
What was Heron Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Heron Therapeutics, Inc.'s earnings per share (EPS) was $-0.12, compared with $-0.09 in 2024.
How has Heron Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Heron Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-0.09) and lowest in 2020 ($-2.50).
How does Heron Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Heron Therapeutics, Inc.'s earnings per share (EPS) ($-0.19) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.